JP2016540778A5 - - Google Patents

Download PDF

Info

Publication number
JP2016540778A5
JP2016540778A5 JP2016536865A JP2016536865A JP2016540778A5 JP 2016540778 A5 JP2016540778 A5 JP 2016540778A5 JP 2016536865 A JP2016536865 A JP 2016536865A JP 2016536865 A JP2016536865 A JP 2016536865A JP 2016540778 A5 JP2016540778 A5 JP 2016540778A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
administered
composition formulated
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016540778A (ja
JP6883987B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/068654 external-priority patent/WO2015085113A1/en
Publication of JP2016540778A publication Critical patent/JP2016540778A/ja
Publication of JP2016540778A5 publication Critical patent/JP2016540778A5/ja
Application granted granted Critical
Publication of JP6883987B2 publication Critical patent/JP6883987B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536865A 2013-12-04 2014-12-04 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法 Expired - Fee Related JP6883987B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361911993P 2013-12-04 2013-12-04
US201361911991P 2013-12-04 2013-12-04
US61/911,993 2013-12-04
US61/911,991 2013-12-04
US201462049299P 2014-09-11 2014-09-11
US62/049,299 2014-09-11
PCT/US2014/068654 WO2015085113A1 (en) 2013-12-04 2014-12-04 Methods for treatment of wound healing utilizing chemically modified oligonucleotides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019179885A Division JP2020033350A (ja) 2013-12-04 2019-09-30 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法

Publications (3)

Publication Number Publication Date
JP2016540778A JP2016540778A (ja) 2016-12-28
JP2016540778A5 true JP2016540778A5 (https=) 2018-01-18
JP6883987B2 JP6883987B2 (ja) 2021-06-09

Family

ID=53274140

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016536865A Expired - Fee Related JP6883987B2 (ja) 2013-12-04 2014-12-04 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
JP2019179885A Pending JP2020033350A (ja) 2013-12-04 2019-09-30 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019179885A Pending JP2020033350A (ja) 2013-12-04 2019-09-30 化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法

Country Status (7)

Country Link
US (1) US20160304875A1 (https=)
EP (1) EP3077050B1 (https=)
JP (2) JP6883987B2 (https=)
KR (1) KR20160110370A (https=)
CN (1) CN105960265A (https=)
CA (1) CA2932753A1 (https=)
WO (1) WO2015085113A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2715289C (en) 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP3494790A1 (en) 2010-03-02 2019-06-12 Phio Pharmaceuticals Corp. Effective sensitizing dose of a gelled immunomodulating topical composition
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
CN103200945B (zh) 2010-03-24 2016-07-06 雷克西制药公司 眼部症候中的rna干扰
EP3560503B1 (en) 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
WO2015168108A2 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic targeting mdm2 or mycn
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
EP3862005A1 (en) 2015-07-06 2021-08-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US20210052631A1 (en) * 2015-09-25 2021-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2017070151A1 (en) 2015-10-19 2017-04-27 Rxi Pharmaceuticals Corporation Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
US12544344B2 (en) 2017-04-19 2026-02-10 Phio Pharmaceuticals Corp. Topical delivery of nucleic acid compounds
CN111773392B (zh) * 2020-05-25 2023-04-07 河南省生物工程技术研究中心 一种人血白蛋白/寡核苷酸纳米颗粒及其制备方法和用途
CN111557913B (zh) * 2020-07-07 2022-05-31 中国科学院空天信息创新研究院 靶向癫痫细胞的纳米光敏复合物及调控检测系统
CN113092461B (zh) * 2021-04-09 2023-08-22 四川大学华西医院 一种均相二维可视化/荧光分析方法及应用
CN113842496B (zh) * 2021-09-28 2022-07-29 五峰赤诚生物科技股份有限公司 一种创面液体敷料及其制备方法

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4201860A (en) 1978-05-09 1980-05-06 Bristol-Myers Company Purine derivatives
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4810646A (en) 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5082936A (en) 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
ZA902710B (en) 1989-05-22 1991-12-24 Univ Georgia Res Found Enzyme luminescence assay
US5032401A (en) 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
EP0491829B1 (en) 1989-09-08 1997-06-04 Alpha Beta Technology, Inc. Composition for immune system activation
JPH05503952A (ja) 1989-09-08 1993-06-24 アルファ ベータ テクノロジー,インコーポレイティッド 可溶性グルカン類の製造方法
WO1992003568A1 (en) 1990-08-13 1992-03-05 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
CA2040374C (en) 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
EP0547142A1 (en) 1990-08-28 1993-06-23 Epoch Pharmaceuticals, Inc. Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
GB9022560D0 (en) 1990-10-17 1990-11-28 G B Biotechnology Limited Processing of waste
WO1994008003A1 (en) 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5525719A (en) 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
US5214135A (en) 1991-08-30 1993-05-25 Chemgenes Corporation N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
TW393513B (en) 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
NZ263985A (en) 1993-03-31 1997-07-27 Hybridon Inc Oligonucleotide complementary to an essential amino acid sequence of influenza virus
US5428149A (en) 1993-06-14 1995-06-27 Washington State University Research Foundation Method for palladium catalyzed carbon-carbon coulping and products
US5580972A (en) 1993-06-14 1996-12-03 Nexstar Pharmaceuticals, Inc. Purine nucleoside modifications by palladium catalyzed methods
US5652359A (en) 1993-12-02 1997-07-29 Epoch Pharmaceuticals, Inc. Oligonucleotides containing n-methyl thiolated bases having antiviral activity
CA2181546A1 (en) 1994-02-18 1995-08-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US5646126A (en) 1994-02-28 1997-07-08 Epoch Pharmaceuticals Sterol modified oligonucleotide duplexes having anticancer activity
US5651981A (en) 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
US5777153A (en) 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
AUPN398295A0 (en) 1995-07-05 1995-07-27 Carlton And United Breweries Limited Chemical compounds and processes for their production
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
US6020483A (en) 1998-09-25 2000-02-01 Nexstar Pharmaceuticals, Inc. Nucleoside modifications by palladium catalyzed methods
DK1146908T3 (da) * 1999-01-27 2005-10-10 Becker David Dr Formuleringer omfattende antisense-nukleotider mod connexiner
US8017742B2 (en) 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
US20040072785A1 (en) 1999-11-23 2004-04-15 Wolff Jon A. Intravascular delivery of non-viral nucleic acid
US7098030B2 (en) 1999-12-31 2006-08-29 Mirus Bio Corporation Polyampholytes for delivering polyions to a cell
JP5154728B2 (ja) 2000-07-24 2013-02-27 クレニツキー・ファーマシューティカルズ,インコーポレイテッド 神経栄養活性を有する置換5−アルキニルピリミジン
WO2002012348A2 (en) 2000-08-03 2002-02-14 Abac R & D Gmbh Isolation of glucan particles and uses thereof
US6476003B1 (en) 2000-11-06 2002-11-05 Immusonic, Inc. Method for preparing small particle size glucan in a dry material
FR2818642B1 (fr) 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US7786094B2 (en) 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20030157030A1 (en) 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
AU2004206955A1 (en) * 2003-01-21 2004-08-05 Archemix Corp. Aptamer therapeutics useful in ocular pharmacotherapy
DE10302421A1 (de) 2003-01-21 2004-07-29 Ribopharma Ag Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
US20050026286A1 (en) 2003-03-05 2005-02-03 Jen-Tsan Chi Methods and compositions for selective RNAi mediated inhibition of gene expression in mammal cells
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
US20060178327A1 (en) 2003-05-30 2006-08-10 Yeung Wah Hin A Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
CN101507822B (zh) * 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
CA3059497A1 (en) * 2003-12-03 2005-06-16 Ocunexus Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
US20050265957A1 (en) 2004-04-08 2005-12-01 Monahan Sean D Polymerized formamides for use in delivery of compounds to cells
EP2338332B1 (en) 2004-05-20 2014-02-12 Eden Research Plc Hollow glucan particle or cell wall particle encapsulating a terpene component
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子(CTGF)RNA干擾(RNAi)抑制技術
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
ATE526991T1 (de) 2005-10-24 2011-10-15 Univ Massachusetts Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
WO2007084797A1 (en) 2006-01-23 2007-07-26 Abbott Laboratories Chemically modified polycation polymer for sirna delivery
US9878043B2 (en) 2006-06-23 2018-01-30 Engeneic Molecular Delivery Pty Ltd Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
US20080039415A1 (en) 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
AU2007299705B2 (en) 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20090043367A1 (en) 2007-08-09 2009-02-12 Yitzhak Zilberman Apparatus and methods for removing an electronic implant from a body
CA2713379A1 (en) 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
CA2715289C (en) 2008-02-11 2019-12-24 Rxi Pharmaceuticals Corporation Modified rnai polynucleotides and uses thereof
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
NZ601660A (en) * 2008-08-25 2014-05-30 Excaliard Pharmaceuticals Inc Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
WO2010027831A1 (en) * 2008-08-25 2010-03-11 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US8644189B1 (en) 2010-02-17 2014-02-04 Sprint Communications Company L.P. Wireless communication device that transmits geographic location information in router advertisement acknowledgement messages
EP3560503B1 (en) * 2010-03-24 2021-11-17 Phio Pharmaceuticals Corp. Rna interference in dermal and fibrotic indications
PT2670411T (pt) * 2011-02-02 2019-06-18 Excaliard Pharmaceuticals Inc Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas
US8802839B2 (en) * 2011-07-15 2014-08-12 Fibrogen, Inc. Connective tissue growth factor antisense oligonucleotides

Similar Documents

Publication Publication Date Title
JP2016540778A5 (https=)
Wang et al. Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance
Dickinson et al. A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension
Fan et al. MicroRNA-210 promotes angiogenesis in acute myocardial infarction
AU2013248981B2 (en) Mirna modulators of thermogenesis
Shibata et al. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model
CA2978431C (en) Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
JP2019527563A5 (https=)
JP2016506240A5 (https=)
CN113412334A (zh) 用于治疗癌症的质粒构建体和使用方法
US20210139997A1 (en) Treatment of angiogenesis disorders
Tang et al. Gene therapy strategies to improve strength and quality of flexor tendon healing
RU2015155332A (ru) Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение
JP2019511216A5 (https=)
WO2015164818A1 (en) Multiple targeted rnai for the treatment of cancers
JP2017528441A (ja) Myh7bの阻害剤およびその使用
EP3134528A1 (en) Multiple targeted rnai for the treatment of cancers
Wang et al. Regression of atherosclerosis plaques in apolipoprotein E−/− mice after lentivirus-mediated RNA interference of CD40
JP2011520781A5 (https=)
CN106591308A (zh) 一种改善人肺腺癌厄洛替尼的耐药性的shRNA
Tamama et al. Early growth response genes signaling supports strong paracrine capability of mesenchymal stem cells
JP2024529930A5 (https=)
CN107184984B (zh) Rpl10的抑制剂在制备治疗卵巢癌的药物中的应用
Lin et al. Inhibition of transforming growth factor- β type I receptor signaling by RNA interference suppresses the proliferation, collagen synthesis, and inflammation factors in human embryonic lung fibroblasts
Chu Therapeutic Applications: Strategies and Molecules Targeting the IL-17/Th17 Pathway